Literature DB >> 20150829

Cytochrome P450 2C9-CYP2C9.

Derek Van Booven1, Sharon Marsh, Howard McLeod, Michelle Whirl Carrillo, Katrin Sangkuhl, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20150829      PMCID： PMC3201766          DOI： 10.1097/FPC.0b013e3283349e84

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  86 in total

1.  The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.

Authors:  J van der Weide; L S Steijns; M J van Weelden; K de Haan
Journal:  Pharmacogenetics       Date:  2001-06

2.  A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology.

Authors:  Matthew G Soars; Harry V Gelboin; Kristopher W Krausz; Robert J Riley
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

3.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Authors:  T H Sullivan-Klose; B I Ghanayem; D A Bell; Z Y Zhang; L S Kaminsky; G M Shenfield; J O Miners; D J Birkett; J A Goldstein
Journal:  Pharmacogenetics       Date:  1996-08

4.  High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.

Authors:  E García-Martín; C Martínez; J M Ladero; F J Gamito; J A Agúndez
Journal:  Eur J Clin Pharmacol       Date:  2001-04       Impact factor: 2.953

5.  Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.

Authors:  Y R Yoon; J H Shon; M K Kim; Y C Lim; H R Lee; J Y Park; I J Cha; J G Shin
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

6.  Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen.

Authors:  J O Miners; S Coulter; R H Tukey; M E Veronese; D J Birkett
Journal:  Biochem Pharmacol       Date:  1996-04-26       Impact factor: 5.858

7.  [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10.

Authors:  A D Rodrigues; M J Kukulka; E M Roberts; D Ouellet; T R Rodgers
Journal:  Drug Metab Dispos       Date:  1996-01       Impact factor: 3.922

8.  CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients.

Authors:  G Chen; S Jiang; G Mao; S Zhang; X Hong; G Tang; Z Li; X Liu; Y Zhang; H Xing; B Wang; Y Yu; X Xu
Journal:  Methods Find Exp Clin Pharmacol       Date:  2006 Jan-Feb

Review 9.  Interactions of warfarin with drugs and food.

Authors:  P S Wells; A M Holbrook; N R Crowther; J Hirsh
Journal:  Ann Intern Med       Date:  1994-11-01       Impact factor: 25.391

10.  Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations.

Authors:  Jue Quin Yang; Sandrine Morin; Céline Verstuyft; Li An Fan; Yong Zhang; Chun Di Xu; Véronique Barbu; C Funck-Brentano; Patrice Jaillon; Laurent Becquemont
Journal:  Fundam Clin Pharmacol       Date:  2003-06       Impact factor: 2.748
View more
  70 in total

1.  Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China.

Authors:  Yongjun He; Hua Yang; Tingting Geng; Tian Feng; Dongya Yuan; Longli Kang; Manling Luo; Tianbo Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.

Authors:  Pierre-Eric Juif; Margaux Boehler; Yves Donazzolo; Shirin Bruderer; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2017-06-21       Impact factor: 2.953

Review 3.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

4.  In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population.

Authors:  Da-peng Dai; Yu-han Wang; Shuang-hu Wang; Pei-wu Geng; Li-ming Hu; Guo-xin Hu; Jian-ping Cai
Journal:  Acta Pharmacol Sin       Date:  2013-09-30       Impact factor: 6.150

5.  Pharmacogenomics and bioinformatics: PharmGKB.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

6.  Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan.

Authors:  Abdoljalal Marjani; Aman Mohammad Gharanjik
Journal:  Indian J Clin Biochem       Date:  2017-05-26

7.  Multivariate analysis of the relation between diet and warfarin dose.

Authors:  Morten Arendt Rasmussen; Jane Skov; Else-Marie Bladbjerg; Johannes J Sidelmann; Marianne Vamosi; Jørgen Jespersen
Journal:  Eur J Clin Pharmacol       Date:  2011-09-21       Impact factor: 2.953

8.  Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.

Authors:  Christopher C Coss; Amanda Jones; James T Dalton
Journal:  Invest New Drugs       Date:  2016-04-22       Impact factor: 3.850

9.  Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.

Authors:  Wenndy Hernandez; Keston Aquino-Michaels; Katarzyna Drozda; Shitalban Patel; Young Jeong; Harumi Takahashi; Larisa H Cavallari; Minoli A Perera
Journal:  Transl Res       Date:  2014-11-22       Impact factor: 7.012

10.  Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism.

Authors:  Sonia J Parikh; Chiara M Evans; Juliet O Obi; Qinghai Zhang; Keiko Maekawa; Karen C Glass; Manish B Shah
Journal:  Mol Pharmacol       Date:  2020-09-16       Impact factor: 4.436
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.